Literature DB >> 24161922

HCMV infection of humanized mice after transplantation of G-CSF-mobilized peripheral blood stem cells from HCMV-seropositive donors.

Morgan Hakki1, Devorah C Goldman2, Daniel N Streblow3, Kimberly L Hamlin2, Craig N Krekylwich3, William H Fleming2, Jay A Nelson4.   

Abstract

Human cytomegalovirus (HCMV) infection, including primary infection resulting from transmission from a seropositive donor to a seronegative recipient (D(+)/R(-)), remains a significant problem in the setting of peripheral blood stem cell transplantation (PBSCT). The lack of a suitable animal model for studying HCMV transmission after PBSCT is a major barrier to understanding this process and, consequently, developing novel interventions to prevent HCMV infection. Our previous work demonstrated that human CD34(+) progenitor cell-engrafted NOD-scid IL2Rγc(null) (NSG) mice support latent HCMV infection after direct inoculation and reactivation after treatment with granulocyte colony-stimulating factor. To more accurately recapitulate HCMV infection in the D(+)/R(-) PBSCT setting, granulocyte colony-stimulating factor-mobilized peripheral blood stem cells from seropositive donors were used to engraft NSG mice. All recipient mice demonstrated evidence of HCMV infection in liver, spleen, and bone marrow. These findings validate the NSG mouse model for studying HCMV transmission during PBSCT.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytomegalovirus; Latency; NSG mouse model; Stem cell transplantation; Transmission

Mesh:

Substances:

Year:  2013        PMID: 24161922      PMCID: PMC3922710          DOI: 10.1016/j.bbmt.2013.10.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  11 in total

1.  Quantitative analysis of latent human cytomegalovirus.

Authors:  B Slobedman; E S Mocarski
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection.

Authors:  W Garrett Nichols; Lawrence Corey; Ted Gooley; Chris Davis; Michael Boeckh
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

3.  Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients.

Authors:  Steven A Pergam; Hu Xie; Ravinder Sandhu; Margaret Pollack; Jeremy Smith; Terry Stevens-Ayers; Valeria Ilieva; Louise E Kimball; Meei-Li Huang; Tracy S Hayes; Lawrence Corey; Michael J Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-03       Impact factor: 5.742

4.  Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.

Authors:  B George; N Pati; N Gilroy; M Ratnamohan; G Huang; I Kerridge; M Hertzberg; D Gottlieb; K Bradstock
Journal:  Transpl Infect Dis       Date:  2010-05-11       Impact factor: 2.228

5.  Cytomegalovirus: pathogen, paradigm, and puzzle.

Authors:  Michael Boeckh; Adam P Geballe
Journal:  J Clin Invest       Date:  2011-05       Impact factor: 14.808

6.  Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model.

Authors:  M Shane Smith; Devorah C Goldman; Alexis S Bailey; Dana L Pfaffle; Craig N Kreklywich; Doran B Spencer; Florence A Othieno; Daniel N Streblow; J Victor Garcia; William H Fleming; Jay A Nelson
Journal:  Cell Host Microbe       Date:  2010-09-16       Impact factor: 21.023

7.  Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality.

Authors:  S Matthes-Martin; T Lion; S W Aberle; G Fritsch; A Lawitschka; B Bittner; F Frommlet; H Gadner; C Peters
Journal:  Bone Marrow Transplant       Date:  2003-05       Impact factor: 5.483

Review 8.  Humanized mice for modeling human infectious disease: challenges, progress, and outlook.

Authors:  Nicolas Legrand; Alexander Ploss; Rudi Balling; Pablo D Becker; Chiara Borsotti; Nicolas Brezillon; Jennifer Debarry; Ype de Jong; Hongkui Deng; James P Di Santo; Stephanie Eisenbarth; Elizabeth Eynon; Richard A Flavell; Carlos A Guzman; Nicholas D Huntington; Dina Kremsdorf; Michael P Manns; Markus G Manz; Jean-Jacques Mention; Michael Ott; Chozhavendan Rathinam; Charles M Rice; Anthony Rongvaux; Sean Stevens; Hergen Spits; Hélène Strick-Marchand; Hitoshi Takizawa; Anja U van Lent; Chengyan Wang; Kees Weijer; Tim Willinger; Patrick Ziegler
Journal:  Cell Host Microbe       Date:  2009-07-23       Impact factor: 21.023

9.  Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.

Authors:  Christopher M Walker; Jo-Anne H van Burik; Todd E De For; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2007-09       Impact factor: 5.742

Review 10.  The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy.

Authors:  Michael Boeckh; W Garrett Nichols
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113

View more
  14 in total

1.  Engraftment and lineage potential of adult hematopoietic stem and progenitor cells is compromised following short-term culture in the presence of an aryl hydrocarbon receptor antagonist.

Authors:  Angel Gu; Monica Torres-Coronado; Chy-Anh Tran; Hieu Vu; Elizabeth W Epps; Janet Chung; Nancy Gonzalez; Suzette Blanchard; David L DiGiusto
Journal:  Hum Gene Ther Methods       Date:  2014-08       Impact factor: 2.396

Review 2.  Humanized mouse models of human cytomegalovirus infection.

Authors:  Lindsey B Crawford; Daniel N Streblow; Morgan Hakki; Jay A Nelson; Patrizia Caposio
Journal:  Curr Opin Virol       Date:  2015-06-25       Impact factor: 7.090

Review 3.  Cellular reservoirs of latent cytomegaloviruses.

Authors:  Matthias J Reddehase; Niels A W Lemmermann
Journal:  Med Microbiol Immunol       Date:  2019-04-22       Impact factor: 3.402

4.  Human cytomegalovirus G protein-coupled receptor US28 promotes latency by attenuating c-fos.

Authors:  Benjamin A Krishna; Monica S Humby; William E Miller; Christine M O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-15       Impact factor: 11.205

5.  Human Cytomegalovirus Latency: Approaching the Gordian Knot.

Authors:  Felicia Goodrum
Journal:  Annu Rev Virol       Date:  2016-08-04       Impact factor: 10.431

Review 6.  Humanized Mouse Models of Clinical Disease.

Authors:  Nicole C Walsh; Laurie L Kenney; Sonal Jangalwe; Ken-Edwin Aryee; Dale L Greiner; Michael A Brehm; Leonard D Shultz
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

Review 7.  A Hitchhiker's guide to humanized mice: new pathways to studying viral infections.

Authors:  Jessica Katy Skelton; Ana Maria Ortega-Prieto; Marcus Dorner
Journal:  Immunology       Date:  2018-03-09       Impact factor: 7.397

Review 8.  Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development.

Authors:  Giuseppe Gerna; Daniele Lilleri
Journal:  Vaccines (Basel)       Date:  2020-04-23

Review 9.  Humanized Mice for Infectious and Neurodegenerative disorders.

Authors:  Prasanta K Dash; Santhi Gorantla; Larisa Poluektova; Mahmudul Hasan; Emiko Waight; Chen Zhang; Milica Markovic; Benson Edagwa; Jatin Machhi; Katherine E Olson; Xinglong Wang; R Lee Mosley; Bhavesh Kevadiya; Howard E Gendelman
Journal:  Retrovirology       Date:  2021-06-05       Impact factor: 3.768

Review 10.  HCMV miRNA Targets Reveal Important Cellular Pathways for Viral Replication, Latency, and Reactivation.

Authors:  Nicole L Diggins; Meaghan H Hancock
Journal:  Noncoding RNA       Date:  2018-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.